IM Cannabis (IMCC)

In Israel, IM Cannabis operates through Focus Medical Herbs Ltd., which holds a cultivation licence to breed, grow, and supply medical cannabis products. This gives the company a direct role in the production side of the cannabis value chain, supporting its ability to serve patients and distribution partners in a market where medical cannabis has been established for many years.

Germany is also an important market for the company and has become a key source of revenue. The German medical cannabis market is pharmacy-based and highly regulated, with products supplied through compliant import, distribution, and wholesale channels. IM Cannabis sells medical cannabis and related products into this environment, where demand is influenced by physician prescribing, reimbursement practices, product availability, and evolving regulation.

The company’s business model depends on navigating different national cannabis laws, quality standards, import rules, and patient access systems. Unlike recreational cannabis companies that focus on consumer retail, IM Cannabis is primarily positioned around medical use and the supply of regulated products to patients through healthcare channels.

For investors, IM Cannabis offers exposure to the international medical cannabis sector, particularly in Europe and Israel. Its performance is shaped by regulatory developments, pricing pressure, cultivation and supply costs, distribution agreements, and the pace at which medical cannabis adoption grows in its target markets.